Premium
Goniothalamin and Celocoxib therapies on the preneoplastic and neoplastic prostatic lesions in the transgenic adenocarcinoma of the mouse prostate model (TRAMP) (1048.8)
Author(s) -
Cag Valeria,
Kido Larissa,
Montico Fabio,
Dall Pozzo Caroline,
Carvalho João,
Costa Debora,
Pilli Ronaldo
Publication year - 2014
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.28.1_supplement.1048.8
Subject(s) - tramp , prostate , celecoxib , medicine , prostate cancer , adenocarcinoma , immunohistochemistry , inflammation , genetically modified mouse , cancer research , pathology , cancer , transgene , biology , biochemistry , gene
Inflammation plays an important role on prostate diseases. The aim of this study was to evaluate and compare the structural and molecular features of the ventral lobe from TRAMP mice undergoing Celecoxib treatment, a nonsteroidal anti‐inflammatory, and Goniothalamin, a synthetic substance, exhibiting anti‐inflammatory and antiproliferative properties. The mice were divided into: Control groups; Tramp: 8 week‐old mice; Tramp:12‐week‐old mice. Treated groups: Celecoxib‐10mg/kg; Goniothalamin‐150mg/kg. The ventral lobe was collected after 4 weeks for light microscopy, immunohistochemistry and western blotting. Structural analysis showed that TRAMP mice developed progressive forms of preneoplastic and neoplastic lesions during their lifetime. Both treatments led to a decrease for cell proliferation and also inflammatory cells. The Celocoxib treatment showed decreased COX‐2, IGFR‐1, STAT‐3 and IL‐17 immunoreactivities. Goniothalamin treatment displayed a stronger IGFR‐1, STAT‐3 and IL‐17 reduction, in contrast to COX‐2 with no change. Thus, both treatments were effective in reducing the progression of prostatic lesions and inflammation. However, the Goniothalamin treatment suggested the most significant effect on the pro‐inflammatory cytokine and on a transcription factor signal transducer, acting in many pro‐oncogenic signals, thus delaying prostate cancer progression. Grant Funding Source : Research Foundation of the State of Sao Paulo (2012/03010‐4/ 2013/01294‐8)